EndoChoice ships 27 Fuse systems in Q2, FDA approves ORBERA device for obesity treatment & more – 4 GI/endoscopy company key notes

Here are four recent news updates on gastroenterology and endoscopy companies.

TheStreet upgraded its rating of AbbVie stock to "buy," according to a Dakota Financial News report.

ORBERA Intragastric Balloon, an Apollo Endosurgery device designed to treat obesity, earned FDA approval.

Boston Scientific shares have rallied 40.1 percent over the past 52 weeks, according to the Insider Trading Report.

EndoChoice reported $18.6 million in revenue, up 27 percent year-over-year. The company shipped 27 Fuse systems during the quarter. EndoChoice has installed 87 systems since Fuse launched.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast